Nestlé Health Science plots next steps for C. diff drug Vowst after robust uptake
After a better-than-expected launch, Nestlé Health Science is planning its next commercialization moves for Vowst, an oral pill to treat recurring Clostridioides difficile, or C. diff, infections. The first-of-its-kind treatment, based on bacterial spores purified from human stool, was approved in April and launched in June. Since then, Vowst has